Key facts
- It has raised $1.6M; the latest was Later Stage VC ($420K) in Dec 2025.
- Notable investors include European Innovation Council, Unicorn Factory Lisboa, Global Health Accelerator, IGNITE MedTech, Innovation Network for Advanced Materials — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for RUBYnanomed
- ·The full record, as it builds
Funding rounds
No funding rounds for RUBYnanomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RUBYnanomed
Developer of a cancer progression device designed to monitor and treat cancer in patients. The company's device has developed a precise cancer snapshot tool that isolates all types of circulating tumor cells from unprocessed whole blood, which helps in the treatment of cancer by monitoring metastatic disease, enabling oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient.
- Sector
- Healthcare
- HQ
- Braga, Portugal
- Founded
- 2018
- Employees
- 10
- Website
- rubynanomed.com/
- Ownership
- Privately Held (backing)
RUBYnanomed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RUBYnanomed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RUBYnanomed in its N-PORT filings yet. We sweep new filings monthly.